How far along are we in revealing the connection between metformin and colorectal cancer?
| Autor: | Maja Cigrovski Berković, Ines Bilic-Curcic, Anna Mrzljak, Danko Mikulić |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Opinion Review
Oncology metformin type 2 diabetes mellitus colorectal cancer chemoprevention recurrence-free survival surgery medicine.medical_specialty Colorectal Neoplasms* / drug therapy Colorectal cancer Type 2 diabetes medicine.disease_cause Chemoprevention 03 medical and health sciences 0302 clinical medicine Hypoglycemic Agents / therapeutic use Internal medicine Diabetes mellitus Type 2 diabetes mellitus Diabetes Mellitus Type 2* / drug therapy medicine Hyperinsulinemia Hypoglycemic Agents Humans business.industry Diabetes Mellitus Type 2* / complications Gastroenterology Cancer General Medicine Colonic Neoplasms Recurrence-free survival medicine.disease Metformin digestive system diseases Oxaliplatin Metformin* / therapeutic use Diabetes Mellitus Type 2 030220 oncology & carcinogenesis Surgery 030211 gastroenterology & hepatology Colorectal Neoplasms business Carcinogenesis medicine.drug |
| Zdroj: | World Journal of Gastroenterology |
| ISSN: | 1007-9327 |
| Popis: | Colorectal cancer (CRC) is among the most prevalent cancers worldwide, and its prevention and reduction of incidence is imperative. The presence of diabetes has been associated with a 30% increased risk of CRC, likely through the mechanism of hyperinsulinemia, which promotes tumorigenesis via the insulin receptor in the epithelium or by insulin-like growth factor pathways, inflammation, or adipokines, inducing cancer cell proliferation and cancer spread. Metformin, the first-line agent in treating type 2 diabetes, has a chemopreventive role in CRC development. Additionally, preclinical studies suggest synergistic effects of metformin with oxaliplatin in inhibiting in vitro models of colon cancer. Although preclinical studies on the post diagnostic use of metformin were promising and suggested its synergistic effects with chemotherapy, the data on the possible effects of metformin after surgery and other CRC treatment in the clinical setting are less conclusive, and randomized controlled trials are still lacking. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|